VBLT News and Press, Vascular Biogenics Ltd. From 06/04/19

TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:  VBLT ), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the rec...

DelMar Pharmaceuticals (NASDAQ: DMPI )  -41%  on equity offering . More news on: DelMar Pharmaceuticals, Inc., Vascular Biogenics Ltd., Centene Corporation, Stocks on the move, Read more ...

VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03) CA-125 response (GCIG) was reported in 58% of evaluable patients and was predictive of overall survival, in patients treated with a therapeutic dose...

TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, showed a survival ...

TEL AVIV, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, to be held May 31 - ...

Vascular Biogenics Ltd. (NASDAQ:VBLT) Q1 2019 Earnings Conference Call May 15, 2019 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - Chief Executive Officer Amos Ron - Chief Financial Officer Conference Call Participants Soumit Roy - Jones Tra...

VBL Therapeutics (NASDAQ: VBLT ): Q1 GAAP EPS of -$0.12 misses by $0.06 . More news on: Vascular Biogenics Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

TEL AVIV, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update. “As we continue to advance development of VB-111, we are getting a better understanding...

TEL AVIV, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio ...

Vascular Biogenics Ltd. (VBLT) Q4 2018 Results Conference Call March 28, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO Amos Ron - CFO Erez Feige - VP of Business Operations Conference Call Participants Swayampakula Ramakanth - H.C...